MEDICINOVA, INC. Increase Decrease In Operating Lease Liability
MEDICINOVA, INC. (MNOV) reported Increase Decrease In Operating Lease Liability of -$94.42 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- MEDICINOVA, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$48.16K.
- MEDICINOVA, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$46.26K.
- MEDICINOVA, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$43.42K.
- MEDICINOVA, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$46.67K.
- MEDICINOVA, INC. increase decrease in operating lease liability for fiscal 2025 was -$195.01K.
- MEDICINOVA, INC. increase decrease in operating lease liability for fiscal 2024 was -$176.20K.
- MEDICINOVA, INC. increase decrease in operating lease liability for fiscal 2023 was -$194.88K.
- MEDICINOVA, INC. increase decrease in operating lease liability for fiscal 2022 was -$145.51K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$48.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$94.42K 10-Q · filed 2026-08-13 | -$137.84K derived: sum of 3 quarters · filed 2026-08-13 | -$184.51K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$46.26K 10-Q · filed 2026-05-14 | -$89.68K derived: sum of 2 quarters · filed 2026-05-14 | -$136.35K derived: sum of 3 quarters · filed 2026-05-14 | -$190.06K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$43.42K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$90.09K derived: sum of 2 quarters · filed 2026-03-10 | -$143.80K derived: sum of 3 quarters · filed 2026-08-13 | -$195.01K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$46.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$100.38K derived: sum of 2 quarters · filed 2026-08-13 | -$151.59K 10-Q · filed 2025-11-12 | -$200.25K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$53.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$104.92K 10-Q · filed 2026-08-13 | -$153.57K derived: sum of 3 quarters · filed 2026-08-13 | -$193.80K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$51.21K 10-Q · filed 2026-05-14 | -$99.86K derived: sum of 2 quarters · filed 2026-05-14 | -$140.09K derived: sum of 3 quarters · filed 2026-05-14 | -$176.61K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$48.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$88.88K derived: sum of 2 quarters · filed 2026-03-10 | -$125.40K derived: sum of 3 quarters · filed 2026-03-10 | -$176.20K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$40.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$76.74K derived: sum of 2 quarters · filed 2025-11-12 | -$127.55K 10-Q · filed 2025-11-12 | -$176.03K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$36.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$87.32K 10-Q · filed 2025-08-14 | -$135.80K derived: sum of 3 quarters · filed 2025-08-14 | -$183.64K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$50.81K 10-Q · filed 2025-05-13 | -$99.29K derived: sum of 2 quarters · filed 2025-05-13 | -$147.13K derived: sum of 3 quarters · filed 2025-05-13 | -$196.53K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$48.48K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$96.32K derived: sum of 2 quarters · filed 2025-02-19 | -$145.73K derived: sum of 3 quarters · filed 2025-02-19 | -$194.88K 10-K · filed 2025-02-19 |
| 2023-09-30 | -$47.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$97.25K derived: sum of 2 quarters · filed 2024-11-13 | -$146.40K 10-Q · filed 2024-11-13 | -$188.19K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$49.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$98.56K 10-Q · filed 2024-08-08 | -$140.35K derived: sum of 3 quarters · filed 2024-08-08 | -$188.46K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$49.15K 10-Q · filed 2024-05-09 | -$90.94K derived: sum of 2 quarters · filed 2024-05-09 | -$139.05K derived: sum of 3 quarters · filed 2024-05-09 | -$164.84K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$41.79K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$89.89K derived: sum of 2 quarters · filed 2024-02-15 | -$115.69K derived: sum of 3 quarters · filed 2024-02-15 | -$145.51K 10-K · filed 2024-02-15 |
| 2022-09-30 | -$48.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$73.90K derived: sum of 2 quarters · filed 2023-11-09 | -$103.73K 10-Q · filed 2023-11-09 | -$166.38K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$25.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$55.62K 10-Q · filed 2023-08-09 | -$118.28K derived: sum of 3 quarters · filed 2023-08-09 | -$169.53K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$29.82K 10-Q · filed 2023-05-11 | -$92.48K derived: sum of 2 quarters · filed 2023-05-11 | -$143.73K derived: sum of 3 quarters · filed 2023-05-11 | -$202.10K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$62.66K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-28 | -$113.91K derived: sum of 2 quarters · filed 2023-03-28 | -$172.28K derived: sum of 3 quarters · filed 2023-03-28 | -$231.74K 10-K/A · filed 2023-03-28 |
| 2021-09-30 | -$51.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$109.62K derived: sum of 2 quarters · filed 2022-11-10 | -$169.08K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$58.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$117.83K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$59.46K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$219.54K 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |